After years of randomized trials and nearly two decades of European data detailing peptide receptor radionuclide therapy, Advanced Accelerator Applications (AAA), a Novartis company, is pleased to announced that the FDA has approved the use of this therapy for patients with neuroendocrine tumors. The approval comes at a time when incidence of neuroendocrine cancers of the pancreas, lungs, and intestines are on the rise. About 7 in 100,000 people are
On January 14, 2018, Dr. Thor Halfdanarson and Dr. A. Tuba Kendi from Mayo Clinic Rochester presented to Northwoods NETS. Dr. Tuba, a radiologist from Mayo, has been fronting the Gallium-68 PET/MRI scan center that has been helping detect and diagnose neuroendocrine tumor patients. She is now at the forefront the PRRT (peptide receptor radionuclide therapy) at the Rochester clinic. Dr. Thor presented his vision for the newly designated Neuroendocrine
Happy New Year to all of our NET patients, caregivers, family members, medical support teams and friends around the world. Twenty eighteen is going to be a fantastic year!
You must be logged in to post a comment.